CommercialCoverageMedium impact
08.02.25a, Fidanacogene elaparvovec-dzkt (Beqvez™)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy for Fidanacogene elaparvovec-dzkt (Beqvez™), a pharmacy benefit drug, has been issued and will become effective May 28, 2025. This appears to be a reissued policy update for a specialized medication that will likely affect billing and coverage determination processes.
Action Required
By May 28, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Fidanacogene elaparvovec-dzkt (Beqvez™). Update billing system and staff training materials accordingly once full policy details are obtained.